JO3383B1 - مثبطات cdc7 - Google Patents

مثبطات cdc7

Info

Publication number
JO3383B1
JO3383B1 JOP/2014/0067A JOP20140067A JO3383B1 JO 3383 B1 JO3383 B1 JO 3383B1 JO P20140067 A JOP20140067 A JO P20140067A JO 3383 B1 JO3383 B1 JO 3383B1
Authority
JO
Jordan
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
useful
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0067A
Other languages
English (en)
Inventor
Andrew Woods Timothy
Dean Dally Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3383B1 publication Critical patent/JO3383B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير مركبات أيزوإندولينون، أو ملح مقبول صيدليًا منها، والتي تثبِّط CDC7، وبالتالي يمكن أن تكون مفيدة في علاج السرطان.
JOP/2014/0067A 2013-03-14 2014-03-04 مثبطات cdc7 JO3383B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JO3383B1 true JO3383B1 (ar) 2019-03-13

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0067A JO3383B1 (ar) 2013-03-14 2014-03-04 مثبطات cdc7

Country Status (36)

Country Link
US (1) US9156824B2 (ar)
EP (1) EP2970221B1 (ar)
JP (1) JP6064079B2 (ar)
KR (1) KR101718645B1 (ar)
CN (1) CN105008351B (ar)
AP (1) AP2015008734A0 (ar)
AU (1) AU2014228374B2 (ar)
BR (1) BR112015020466B1 (ar)
CA (1) CA2900773C (ar)
CL (1) CL2015002530A1 (ar)
CR (1) CR20150416A (ar)
CY (1) CY1119199T1 (ar)
DK (1) DK2970221T3 (ar)
EA (1) EA027012B1 (ar)
ES (1) ES2639793T3 (ar)
GT (1) GT201500263A (ar)
HR (1) HRP20171151T1 (ar)
HU (1) HUE033482T2 (ar)
IL (1) IL240962B (ar)
JO (1) JO3383B1 (ar)
LT (1) LT2970221T (ar)
ME (1) ME02805B (ar)
MX (1) MX363438B (ar)
MY (1) MY188145A (ar)
NZ (1) NZ710392A (ar)
PE (1) PE20151654A1 (ar)
PH (1) PH12015502091B1 (ar)
PL (1) PL2970221T3 (ar)
PT (1) PT2970221T (ar)
RS (1) RS56122B1 (ar)
SG (1) SG11201507541PA (ar)
SI (1) SI2970221T1 (ar)
TN (1) TN2015000349A1 (ar)
TW (1) TWI622396B (ar)
UA (1) UA116125C2 (ar)
WO (1) WO2014143601A1 (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388167B2 (en) * 2012-10-15 2016-07-12 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogues thereof
EP2943485B1 (en) 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
TWI662030B (zh) 2013-01-15 2019-06-11 英塞特控股公司 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
ES2689526T3 (es) 2013-03-14 2018-11-14 Janssen Pharmaceutica Nv Moduladores de P2X7
EA029052B1 (ru) 2013-03-14 2018-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節物質
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
HUE047208T2 (hu) 2014-09-12 2020-04-28 Boehringer Ingelheim Int A katepszin-C spirociklikus inhibitorai
WO2016039977A1 (en) 2014-09-12 2016-03-17 Janssen Pharmaceutica Nv P2x7 modulators
AU2015315693B2 (en) 2014-09-12 2020-01-16 Janssen Pharmaceutica Nv P2X7 modulating n-acyl-triazolopyrazines
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AU2017332839B2 (en) * 2016-09-22 2021-11-11 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ.ベー. モノアシルグリセロールリパーゼ調節因子
US20220220125A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
EP2073806B1 (en) * 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) * 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
ME02805B (me) 2018-01-20
MX2015012583A (es) 2016-01-20
RS56122B1 (sr) 2017-10-31
BR112015020466A8 (pt) 2019-11-12
JP6064079B2 (ja) 2017-01-18
BR112015020466B1 (pt) 2022-07-26
EP2970221B1 (en) 2017-06-28
HK1212696A1 (en) 2016-06-17
KR20150119101A (ko) 2015-10-23
DK2970221T3 (en) 2017-07-31
TN2015000349A1 (en) 2017-01-03
ES2639793T3 (es) 2017-10-30
IL240962B (en) 2020-04-30
MX363438B (es) 2019-03-22
EA027012B1 (ru) 2017-06-30
EP2970221A1 (en) 2016-01-20
PH12015502091A1 (en) 2016-01-18
SG11201507541PA (en) 2015-10-29
HRP20171151T1 (hr) 2017-10-06
CL2015002530A1 (es) 2016-03-28
CN105008351B (zh) 2017-03-15
JP2016512498A (ja) 2016-04-28
CN105008351A (zh) 2015-10-28
PL2970221T3 (pl) 2017-11-30
CA2900773C (en) 2018-04-17
CA2900773A1 (en) 2014-09-18
WO2014143601A1 (en) 2014-09-18
AP2015008734A0 (en) 2015-09-30
IL240962A0 (en) 2015-11-30
AU2014228374A1 (en) 2015-08-06
PE20151654A1 (es) 2015-11-12
LT2970221T (lt) 2017-09-11
US9156824B2 (en) 2015-10-13
MY188145A (en) 2021-11-23
GT201500263A (es) 2016-03-02
CY1119199T1 (el) 2018-02-14
SI2970221T1 (sl) 2017-08-31
PT2970221T (pt) 2017-09-22
CR20150416A (es) 2015-09-16
EA201591509A1 (ru) 2015-12-30
TW201521726A (zh) 2015-06-16
BR112015020466A2 (pt) 2017-07-18
TWI622396B (zh) 2018-05-01
US20140275121A1 (en) 2014-09-18
KR101718645B1 (ko) 2017-03-21
AU2014228374B2 (en) 2016-09-01
UA116125C2 (uk) 2018-02-12
PH12015502091B1 (en) 2019-01-11
NZ710392A (en) 2020-05-29
HUE033482T2 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
PH12015502091A1 (en) Cdc7 inhibitors
PH12017500881B1 (en) Aurora a kinase inhibitor
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL268430A (en) Methods for treating cancer using hsp90 inhibitors
EP3247353A4 (en) Heterocyclic itk inhibitors for treating inflammation and cancer
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
MX369691B (es) Inhibidores de glutaminasa y métodos de empleo.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
EP3664803A4 (en) DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
GB201702160D0 (en) Inhibitors for use in therapy
MX2015013021A (es) 5-bromo-indirrubinas.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
NZ711523A (en) Use of sedoheptulose for prevention or treatment of inflammation
WO2014160628A3 (en) Articles and methods for preventing and treating dermatologic adverse events
EP3025711A4 (en) Medicine for preventing or treating hypertension
EP3674398A4 (en) ECHOVIRUS FOR TUMOR TREATMENT
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MX2015014063A (es) Composicion anti tumoral que comprende un inhibidor selectivo pi3kbeta y un inhibidor selectivo pi3kalfa.
HK40031759A (en) Dhodh inhibitor for use in treating hematologic cancers
HK1261928A1 (en) Combination therapy for treating malignancies